DB04859ExperimentalSmall molecule
Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
- Mechanism
- Curator reviewed
Zanapezil inhibits the degradation of acetylcholine, a neurotransmitter, to prevent the reduction of cerebral acetylcholine levels and to enhance the mental function of patients with dementia. It is expected to act selectively on the central nervous system, resulting in fewer peripheral adverse reactions.
- Primary indication
- For the treatment of dementia in subjects with Alzheimer’s disease.Curator reviewed
- Formula / weight
- C25H32N2O · 376.5344 g/mol (avg)
- Also known as
- Zanepezil
- Code names
- TAK-147
Resolves to
Structure
InChIKey
PMBLXLOXUGVTGB-UHFFFAOYSA-NSMILESO=C(CCC1CCN(CC2=CC=CC=C2)CC1)C1=CC2=C(CCCCN2)C=C1Targets
What you can answer from here — as of March 06, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Zanapezil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account